Eli Lilly and Company
LLY
$726.31
-$19.64-2.63%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 2.19B | -57.40M | 1.76B | 1.34B | 1.94B |
| Total Depreciation and Amortization | 387.70M | 411.00M | 366.30M | 362.30M | 375.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 282.90M | 1.04B | -657.40M | -140.70M | 174.20M |
| Change in Net Operating Assets | -3.17B | 793.30M | -840.20M | 164.10M | -824.20M |
| Cash from Operations | -311.90M | 2.19B | 631.90M | 1.73B | 1.66B |
| Capital Expenditure | -1.07B | -970.30M | -738.20M | -668.50M | -500.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.04B | -- | -- | -- | -327.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -809.40M | -2.11B | 279.10M | -20.30M | -115.60M |
| Cash from Investing | -2.92B | -3.08B | -459.10M | -688.80M | -943.50M |
| Total Debt Issued | 4.59B | 97.00M | 0.00 | 3.96B | -243.30M |
| Total Debt Repaid | -- | 1.50B | 0.00 | -1.50B | 0.00 |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -750.00M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.02B | -1.02B | -1.02B | -1.02B | -884.40M |
| Other Financing Activities | -31.60M | -6.80M | -15.60M | -281.00M | -13.70M |
| Cash from Financing | 3.54B | 572.00M | -1.03B | 412.30M | -1.14B |
| Foreign Exchange rate Adjustments | 129.30M | 5.30M | 9.20M | 24.80M | -128.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 437.80M | -313.70M | -851.40M | 1.48B | -550.40M |
